AstraZeneca Plc (AZN)

54.04
0.24 0.45
NYSE : Health Technology
Prev Close 53.80
Open 53.85
Day Low/High 53.72 / 54.50
52 Wk Low/High 36.15 / 57.44
Volume 4.30M
Avg Volume 4.91M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 140.59B
EPS 0.50
P/E Ratio 51.77
Div & Yield 1.37 (2.57%)

AstraZeneca downgraded at Jefferies

AstraZeneca's Ailment Doesn't Look Treatable

AstraZeneca's Ailment Doesn't Look Treatable

AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area. 

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

Asian, European Stocks Surge in the Morning of Fed Interest Rate Day

And four other things you need to know now.

Why Relypsa Is a New 'Best Idea'

Why Relypsa Is a New 'Best Idea'

It is hard to see the biotech firm not becoming a takeover target.

Greek Parliament Approves Reforms Required by Creditors

And four other things you need to know now.

Chinese Stocks Close Into Bull Market Territory

And four other things you need to know now.

4 Reasons to Buy High Dividend Yield Equities in Europe

As bond yields go negative, dividend yields shine. 

Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level

Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level

Our strategy for the stock is to look to buy available weakness in the next few weeks.

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

Overpriced and Vulnerable: 9 Stocks to Avoid

Overpriced and Vulnerable: 9 Stocks to Avoid

A look at the high-priced and weak among the most expensive sectors.

Dynavax: Revisiting A 'Best Idea'

Dynavax: Revisiting A 'Best Idea'

This small-cap biotech firm could be in the early stages of a big move.

China Forbids Big Shareholders to Sell Stocks for 6 Months

And four other things you need to know now.

Here Are 3 Charts Showing You Why Illumina Is a Marvel

Here Are 3 Charts Showing You Why Illumina Is a Marvel

It's almost impossible to get too excited about its success.

The Amazing Thing About the Receptos Takeover Chatter

That this could be such an open secret is beyond me.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

Here Are 3 Stocks With Huge Potential

Two are biotechs and one is in cyber security.

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Lags Markets on Forex; Boeing Soars on 737 Production

Delta Air Lines (DAL) lagged the S&P 500 Tuesday after reporting a steep decline in passenger unit revenue in May.

Europe Officials 'Annoyed' With Greece

And four other things you need to know now.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Dynavax Technologies: A New 'Best Idea'

Dynavax Technologies: A New 'Best Idea'

This vaccine maker is now closer to several important milestones.

Those Sensitive Biotechs

They are prone to being whipsawed by news.

Go With What's Worked, Part 2

Let's look at the other groups that caught fire.

Five Things to Know Now: Another Banking Probe

U.K. authorities launch another probe into banks' conduct.

Profit From the Longer Life Spans, Part 1

Profit From the Longer Life Spans, Part 1

Americans are living much longer these days -- and there are a number of ways to invest.

Five Things to Know Now: Amazon Tumbles

Shares nosedived in after-hours trading.

A Memo to the Activists

Stop picking on PepsiCo, Allergan and Apple.

This Morning's Market Setup

Where it began. "As I mentioned earlier, the divergences seen since late summer are starting to weigh on stocks:  "Underperformance of the Russell Index. "Weakening in the cumulative advance/decline line of the Nasdaq. "Contraction in the number of ...

Medtronic and Covidien Deal Is Tax Strategy Guiding Health Care M&A

Medtronic and Covidien Deal Is Tax Strategy Guiding Health Care M&A

In the immediate aftermath of the Obamacare rollout, pharma and healthcare M&A fell. Now, however, it's back up, on deals like Monday morning's Covidien - Medtronic announcement,

A 'Who's Who' of Tax-Domicile Targets

A 'Who's Who' of Tax-Domicile Targets

Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.